Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

 Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

Shots:

  • The approval is based on results of ongoing P-III CONVERT study conducted at 18 countries with 125 sites assessing Arikayce + guideline-based therapy (GBT) vs GBT alone with refractory nontuberculous mycobacterial (NTM) lung disease caused by MAC
  • P-III CONVERT study Results: ARIKAYCE+GBT reduced evidence of NTM lung disease caused by MAC in sputum @6 mos. (29% vs 9%), showing its safety and efficacy
  • ARIKAYCE is a novel therapy approved in the US for patients with MAC lung disease an also first product approved via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

Click here to read full press release/ article | Ref: Insmed | Image: Insmed

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post